Form 4: Guardant Health CCO Sells Shares Under 10b5-1 Plan

Guardant Health's Chief Commercial Officer, Chris Freeman, sold 31,252 shares of common stock for over $3.2 million on December 5, 2025, under a pre-arranged trading plan.

Summary

• Chris Freeman, the Chief Commercial Officer of Guardant Health, Inc. (GH), reported the sale of common stock.
• A total of 31,252 shares of common stock were disposed of in multiple transactions on December 5, 2025.
• The sales were executed at weighted average prices ranging from $101.4027 to $106.7081 per share.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Chris Freeman directly beneficially owns 25,987 shares of Guardant Health common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a negative signal, the disclosure of a 10b5-1 plan mitigates the negative interpretation, suggesting a pre-planned liquidity event rather than a lack of confidence in the company's future.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than a reaction to recent company performance or immediate market conditions.

Negatives

• A significant sale of 31,252 shares by a key executive, the Chief Commercial Officer, could be perceived negatively by some investors, even if pre-planned.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

This filing is an insider transaction report and does not provide information directly related to broader industry trends or competitors. It reflects an individual executive's stock activity within the company.

Stakeholder Impact

• Shareholders: May interpret the executive's sale as a signal, though the 10b5-1 plan suggests it's not based on new negative information. Could lead to short-term price volatility.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

While insider selling typically warrants caution, the disclosure that these sales were conducted under a Rule 10b5-1 plan suggests a pre-arranged transaction for personal financial planning rather than a reaction to adverse company developments. Therefore, it does not necessarily indicate a change in the company's fundamental outlook, leading to a 'hold' recommendation for existing investors to monitor future developments, and for potential investors to consider broader company fundamentals beyond this single transaction.

Keywords

Guardant Health, GH, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Chris Freeman